Plain-English translation of NCT06334575 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing how a lung medication called an inhaled corticosteroid (ICS) works in people with chronic obstructive pulmonary disease (COPD) who have quit smoking. Researchers want to understand why some patients respond better to this medication than others, and whether a patient's blood cell counts and lung bacteria can predict who will benefit most. The study will help doctors personalize COPD treatment in the future.
Not all COPD patients respond equally well to this type of lung medication, and doctors don't yet have reliable ways to predict who will benefit. This trial aims to find biological markers—measurable signs in blood and lungs—that can help identify which patients are most likely to improve with the medication, so treatment can be tailored more effectively.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to either take the lung medication or continue without it for the study period. During the trial, you would visit the research clinic multiple times for breathing tests, blood draws, and sputum samples so researchers can analyze your molecular and bacterial signatures. The study involves international sites, so the exact schedule and duration would depend on which location you join, but you would need to commit to completing all required visits and tests.
AI-generated summary from trial data · Jun 8, 2026 · Not medical advice
Germany
Netherlands
Spain
United Kingdom